WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 8 |
3.09 |
ml/min/100g |
0.18 |
0.51 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99951 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 8 |
8.8 |
mmHg/ml/min |
0.5 |
1.41 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99962 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 6 |
8.8 |
mmHg/ml/min |
0.5 |
1.22 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99964 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 16 |
6.8 |
mmHg/ml/min |
0.3 |
1.2 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99999 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 8 |
2.33 |
ml/min/100g |
0.09 |
0.25 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99952 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 11 |
2.28 |
ml/min/100g |
0.07 |
0.23 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99990 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 17 |
16.7 |
mmHg/ml/min |
1.4 |
5.77 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99996 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 16 |
7.1 |
mmHg/ml/min |
0.3 |
1.2 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99998 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 16 |
3.15 |
ml/min/100g |
0.13 |
0.52 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99993 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 7 |
2.16 |
ml/min/100g |
0.18 |
0.48 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99950 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 6 |
2.42 |
ml/min/100g |
0.09 |
0.22 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99954 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 8 |
9.0 |
mmHg/ml/min |
0.4 |
1.13 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99961 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 8 |
9.2 |
mmHg/ml/min |
0.4 |
1.13 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99963 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 17 |
3.3 |
ml/min/100g |
0.11 |
0.45 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99992 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 16 |
3.19 |
ml/min/100g |
0.13 |
0.52 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99994 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 7 |
10.0 |
mmHg/ml/min |
0.6 |
1.59 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99960 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 17 |
1.72 |
ml/min/100g |
0.11 |
0.45 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99991 |
2378 |
WKY |
renal plasma flow to body weight ratio |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
kidney plasma flow trait |
male |
0 days
| 8 |
2.32 |
ml/min/100g |
0.11 |
0.31 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
28 |
days |
99953 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 17 |
6.6 |
mmHg/ml/min |
0.3 |
1.24 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99997 |
2378 |
WKY |
renal vascular resistance |
unilateral nephrectomy (for 28 days) then vehicle control condition |
Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. |
arterial blood pressure trait |
male |
0 days
| 11 |
6.3 |
mmHg/ml/min |
0.4 |
1.33 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
unx |
168 |
days |
99995 |
2378 |